Sparano JA, Crager MR, Tang G, et al. - This study was attempted to evaluate whether the 21-gene recurrence score (RS) is prognostic for distant recurrence (DR) and predictive for chemotherapy benefit in early breast cancer, whereas clinical-pathological factors are only prognostic. Researchers constructed a new tool (RSClin) that integrates RS with tumor grade, tumor size, and age applying a patient-specific meta-analysis enrolling a total of 10,004 women with hormone receptor-positive, human epidermal growth factor receptor 2–negative, and node-negative breast cancer who received endocrine therapy alone in the B-14 (n = 577) and TAILORx (n = 4,854) trials or plus chemotherapy in TAILORx (n = 4,573). They compared Cox models for RSClin with RS alone and clinical-pathological features alone applying likelihood ratio tests. The study found that in node-negative breast cancer, the RSClin tool integrates clinical-pathological and genomic risk to guide adjuvant chemotherapy and gives more individualized information than clinical-pathological or genomic data alone.